Two AIM Stocks In Focus: Proactis Holdings Plc And Oncimmune Holdings Plc

Proactis Holdings PLC

The United Kingdom-based, PROACTIS Holdings PLC (PHD) specialises in B2B eCommerce solutions for leaner, faster and smarter organisations. As the world is shaping up as a digital economy, which thrives on maximum efficiency and driven by business models based on technology. The company has transformed the way goods & services are bought and sold so that buyers and sellers can create maximum value and sustain profitability. The company’s spend management solutions grant control and tracking features for procurement, expenses and advisory services. This can benefit users with savings, productivity, responsiveness and risk mitigation. The company’s sales solutions can help users find qualified buyers and sellers. In addition, the sales solutions of the company help the users in streamlining of the invoicing process and manage the cash flows of the company. Furthermore, the company has a secure network, which helps the users to connect with thousands of businesses and find the best deals, faster interaction and cost optimisation. PROACTIS Source-to-Contract, PROACTIS Purchase-to-Pay and PROACTIS Supplier Network solutions are some popular products of the company.

PHD-Financial performance for Financial Year 2019

The company released its results for the financial year 2019 period ended 31st July 2019 on 31st October 2019. In the fiscal year 2019, the company signed a total contract value of £11.3 million as against £12.1 million in the fiscal year 2018. The company managed to sustain the revenue stream for the coming years. The company’s reported revenues increased by 4 per cent, from £52.2 million in the Financial Year 2018 to £54.1 million in the Financial Year 2019. Annualised recurring revenue (ARR) of the company was maintained at £44.3 million in the Financial Year 2019, which was consistent with the previous fiscal year. The company’s adjusted EBITDA decreased from £17.3 million in Financial Year 2018 to £15.1 million in the Financial Year 2019 and was in accordance with the company’s management. The company’s adjusted EPS decreased from 10.6 pence per share in the Financial Year 2018 to 6.6 pence per share in Financial Year 2019. The company ran into losses this year (FY19) as the loss before tax stood at £25.8 million, the company’s profit before taxation stood at £3.8 million in the financial year 2018. Bank’s debt of the company was reduced to £36.5 million in the fiscal year 2019. The net cash flow of the company increased from £8.4 million in the financial year 2018 to £11.9 million in the Financial Year 2019. The European Union, the United States and the United Kingdom are some geographies where the company has its footprints. The company is not involved in import or export of goods and services across the EU borders and therefore, the company believes that it would be least impacted in case of Brexit. The board expressed its happiness for a significant reduction in company’s debt this year, which will help the company in generating cash and sustain the bottom line.

PHD-Share price analysis

(Source: Thomson Reuters)

While writing (as on 05th November 2019, at 10:05 AM GMT), Proactis Holdings PLC shares were trading at GBX 52.54 per share; plunged by 1.79 per cent as compared to the previous day closing price level. The company’s market capitalisation was around £51.32 million.

PHD shares have clocked a high of GBX 145.00 (as on 18th December 2018) and a low of GBX 28.02 (as on 11 June 2019) in the past year. At the current price point, as quoted in the price chart, the company’s shares were trading 63.76 per cent below the 52-week high price point and 87.50 per cent above the 52-week low price point.

At the time of writing, the stock’s volume before the market close, stood at 12,923. Stock's average daily traded volume for 5 days was 477,617.20; 30 days- 267,952.13 and 90 days – 542,623.89.

In the past 1 month, PHD shares have delivered a positive return of 3.88 per cent. Also, on a YTD (Year-to-Date) time interval, the stock plunged by approximately 60.81 per cent and was up by 0.94 per cent in the last three months.

Oncimmune Holdings PLC

The leading global immunodiagnostics group, Oncimmune Holdings Plc (ONC) founded in 2002, is a cancer diagnosis company, that revolutionises the way cancer is detected. The company aims to detect cancer in early stages by analysing and harnessing the immune system capabilities to respond to this sophisticated disease. The company spans its operations across the United Kingdom, North America and the rest of the world. The company has a range of diagnostic tests which can detect cancer four years before or earlier than the conventional clinical diagnosis. In addition, the company also helps other healthcare companies to develop new cancer-treating methods with the help of sample biobanks and technology platform.

ONC-Recent news

The company recently drew its second trance of credit facility of €8.5 million on 4^th November 2019. Earlier in September, the company drew an initial €5.0 million.

The group has signed an agreement with Biodesix Inc regarding strategic commercialisation for EarlyCDT Lung in the United States. In addition, the company shall also provide Biodesix with reagents and diagnostic plates.

ONC-Financial highlights for FY19

On 31^st October 2019, the company released unaudited results for the Financial Year 2019 period ended 31^st May 2019. The company’s revenue was recorded at £171 thousand in FY19 as against £240 thousand in FY18. The company’s R&D costs were recorded at £1.5 million in FY19 as against £800 thousand in FY18. The company’s net loss stood at £8.0 million in FY19 as against £6.3 million in FY18.  The company had cash balances of £5.4 million in FY19 as compared to £12.95 million in FY18. The company’s operating expenses (excluding share-based charges) were recorded at £7.3 million in FY19 as against £5.7 million in FY18. The company’s net loss (unaudited) was around £8.0 million in FY19 as against £6.3 million in FY18.  The investment in research and development indicates the advancement in the pipeline which is bolstered by a network of distributors and dedicated management.

ONC-Share price performance

(Source: Thomson Reuters)

While writing (as on 05th November 2019, at 12:34 PM GMT), Oncimmune Holdings Plc shares were trading at GBX 60.00 per share; plunged by 4 per cent as compared to the previous day closing price level. The company’s market capitalisation was around £39.69 million.

ONC shares have clocked a high of GBX 138.50 (as on 20th December 2018) and a low of GBX 61.00 (as on 04th November 2019) in the past year. At the current price point, as quoted in the price chart, the company’s shares were trading 56.67 per cent below the 52-week high price point and 1.63 per cent below the 52-week low price point.

At the time of writing, the stock’s volume before the market close, stood at 5,000. Stock's average daily traded volume for 5 days was 21,008.80; 30 days- 25,379.90 and 90 days – 21,433.81.

In the past 1 month, ONC shares have delivered a negative return of 26.04 per cent. Also, on a YTD (Year-to-Date) time interval, the stock plunged by approximately 45.65 per cent and was down by 34.90 per cent in the last three months.